1 2 3	Hemoglobin modifies the effect of hypoxemia on COVID-19 mortality
4	The interaction effect between hemoglobin and
5	hypoxemia on COVID-19 mortality in a sample from
6	Bogotá, Colombia: An exploratory study.
7	
8	Andrés Felipe Patiño-Aldana ¹ , Angela María Ruíz-Sternberg ¹ , Angela María Pinzón-Rondón ^{1*} ,
9	Nicolás Molano-González ¹ , David Rene Rodríguez Lima ²
10	
11	
12	
13	
14	¹ Clinical Research Group, Universidad del Rosario, Bogotá, Colombia
15	² CIMED, Hospital Universitario Mayor - Méderi, Bogotá, Colombia
16	
17	
18	
19	
20	
21	*Corresponding author:
22	E-mail: angela.pinzon@urosario.edu.co
23	
24	
25	

26 **Abstract:**

Purpose: We aimed to assess the effect of hemoglobin (Hb) concentration and oxygenation
 index on COVID-19 patients' mortality risk.

Patients and methods: We retrospectively reviewed sociodemographic and clinical characteristics, laboratory findings, and clinical outcomes from patients admitted to a tertiary care hospital in Bogotá, Colombia. We assessed exploratory associations between oxygenation index and Hb concentration at admission and clinical outcomes. We used a generalized additive model (GAM) to evaluate the nonlinear relations observed and the classification and regression trees (CART) algorithm to assess the interaction effects found.

35 **Results:** From March to July 2020, 643 patients were admitted, of which 52% were male. The 36 median age was 60 years old, and the most frequent comorbidity was hypertension (35.76%). 37 The median value of SpO₂/FiO₂ was 419, and the median Hb concentration was 14.8 g/dL. The 38 mortality was 19.1% (123 patients). Age, sex, and history of hypertension were independently 39 associated with mortality. We described a nonlinear relationship between SpO₂/FiO₂, Hb 40 concentration and neutrophil-to-lymphocyte ratio with mortality and an interaction effect between 41 SpO₂/FiO₂ and Hb concentration. Patients with a similar oxygenation index had different mortality 42 likelihoods based upon their Hb at admission. CART showed that patients with $SpO_2/FiO_2 < 324$, 43 who were older than 62 years, and had an Hb of \geq 16 g/dl had the highest mortality risk (96%). 44 Additionally, patients with $SpO_2/FiO_2 > 324$ but Hb of < 12 and neutrophil-to-lymphocyte ratio of > 45 4 had a higher mortality likelihood (57%). In contrast, patients with SpO₂/FiO₂ > 324 and Hb of > 12 g/dl had the lowest mortality risk (10%). 46

47 **Conclusion:** We found that a decreased SpO_2/FiO_2 increased mortality risk. Extreme values of 48 Hb, either low or high, showed an increase in likelihood of mortality. However, Hb concentration 49 modified the SpO_2/FiO_2 effect on mortality; the likelihood of death in patients with low SpO_2/FiO_2 50 increased as Hb increased.

52 Keywords: Hypoxia; Erythrocytosis; Acute respiratory infection; SARS-CoV-2; Neutrophil-to-

53 lymphocyte ratio; Generalized additive model; Classification and regression tree.

54

55 Introduction

56 On December 31, 2019, SARS-CoV-2 emerged in China and rapidly spread worldwide, with more 57 than 293 million infections and 5.4 million deaths.[1] In Colombia, which is a developing country, 58 as of January 5th, there have been more than 5.2 million cases, with more than 130,000 deaths 59 in the national territory. In Bogota, the most affected city in the country, there have been more 60 than 1.49 million people infected and 27,846 people have died.[2,3]

61

62 Several studies worldwide have associated factors with mortality in COVID-19 patients. Most 63 studies have been consistent with risk factors for severe disease. Studies in Asia reported age, 64 history of smoking, vital signs at admission, albumin, C-reactive protein, and proinflammatory 65 cytokines as risk factors for disease progression. [4,5] Studies in the USA described factors such 66 as oxygenation (SpO₂/FiO₂) at admission, age, heart failure, sex, nursing home residency, 67 respiratory rate, and body mass index (BMI) as the main predictors associated with COVID-19 68 critical illness.[6,7] These factors might be linked to a hyperinflammatory syndrome, which favors 69 an exaggerated immune response and organ failure when facing a viral infection.[8,9]

70

71 Some ecological studies have evaluated COVID-19 mortality in high-altitude places, but the 72 results are contradictory. Some authors reported higher mortality in men younger than 65 years 73 old living in the USA and Mexico at >2,000 m elevation than in those located <1,500 m.[10] Other 74 studies developed in an Andean population (Colombia and Perú) showed a negative correlation 75 between high altitude and COVID-19 mortality and lower mortality excess.[11-13] People who 76 permanently live in high-altitude places develop adaptative mechanisms against low atmospheric 77 oxygen pressure exposure. In locations such as Bogotá, which has an altitude of more than 2,500 78 meters, there is a decrease in mean SpO₂ values among its population.[14] People who live in

high altitude locations develop ventilatory, cardiovascular, reproductive, and even cognitivechanges. [15,16]

81

82 As part of the compensatory mechanisms, erythrocyte concentration in the blood increases. 83 Initially, it is caused by a fast reduction in plasma volume. Additionally, hypoxia leads to an 84 erythropoietic stimulus through hypoxia-inducible factor 1-alpha (HIF1- α) activation that binds 85 hypoxia-inducible factor 1-beta (HIF1- β). Together, they act as a promoting factor for 86 erythropoietin (EPO) stimulating red blood cell (RBC) production.[17] High altitude also leads to 87 hyperventilation driven by an increased tidal volume and respiratory rate. Living in a high-altitude 88 place is related to alveolar and arterial hypoxemia. A person at sea level will have an alveolar 89 oxygen pressure between 90 and 100 mm Hg, a resident at Bogotá will reach a PaO2 between 90 60 and 70 mmHg, while someone at 5,100 m elevation will have a PaO2 of 43 mmHg.[18-20] 91 The adaptative mechanisms allow for the survival of populations conditioned to these harsh 92 environments. However, studies of people living at high altitudes have described increases in the 93 O₂ maximum consumption as they descend to sea level, highlighting the physiologically 94 challenging condition imposed by low oxygen pressures for oxygen uptake and utilization.[18]

95

96 Numerous studies have proposed hemoglobin (Hb) as a biomarker of severe COVID-19.[21] 97 Anemia is a marker of chronic disease and a risk factor in critical ill patients. Limited oxygen-98 carrying capacity and delivery might play a crucial role in organ failure development. Thus, 99 increasing the likelihood of severity and mortality.[21,22] A recent meta-analysis found a lower 100 mean Hb concentration between moderate and severe cases, but did not find significant 101 differences between survivors and nonsurvivors.[21]

102

Adaptative mechanisms to high altitude are related to oxygen intake, transport, and the availability for tissues. Patients with acute respiratory infections who live in high altitude face a convergence between pathological and adaptive processes. Mechanisms that could be

- 106 interrelated moderating the disease outcome. Our research aimed to assess the effect of Hb and
- 107 oxygenation index on COVID-19 mortality.

Materials and methods

109 Study population

110 We performed an observational, retrospective study between March and July 2020. We followed 111 a cohort of COVID-19 patients admitted to the Hospital Universitario Mayor Méderi (HUM) in 112 Bogotá, Colombia. In this study, we used a cutoff date of July 2020. We included patients with 113 confirmed infection of SARS-CoV-2 by RT-PCR or antigen. We excluded patients with a history 114 of anemic, lymphoproliferative, or myelodysplastic syndromes. We also excluded patients with 115 information of permanent residency under 2,500 meters above sea level (MASL) and without 116 complete blood count (CBC) measurement. The Ethics Committee of the Universidad del Rosario 117 approved the research protocol. Qualified professionals carried out all activities and procedures 118 following the principles outlined in the Declaration of Helsinki.

119 Variables and main outcomes

120 Data were collected from clinical records through a comprehensive review of hospital admission 121 information. A CBC was taken only in patients with hospital admission criteria that required 122 laboratory assessments, and who received at least a few hours of in-hospital observation. The 123 CBC was processed in HUM's clinical laboratory using a Sysmex XN-1000 hematology analyzer. 124 In cases of low-flow systems that could not deliver constant FiO₂, we took clinically recorded 125 FiO₂. A nasal cannula increased FiO₂ by approximately 0.4% per liter/min. A nonrebreather mask 126 with a flow output higher than 10 L/min was taken as 100% FiO₂.[23] We calculated variables 127 such as SpO₂/FiO₂, mean arterial pressure (MAP), and neutrophil to lymphocyte ratio (NLR). We 128 defined the discharge condition (alive or dead) as the primary outcome.

129

130 Statistical analysis

131 We reported qualitative variables as frequencies and percentages, and quantitative variables as 132 the means and standard deviations or medians and interguartile ranges, depending on the 133 normality of the distribution (tested by Shapiro–Wilk test). To assess the possible associations 134 with mortality, we performed an exploratory analysis using the Mann-Whitney test or the chi-135 square of independence test for quantitative and qualitative variables, respectively. We made a 136 purposeful selection of covariates for the multivariate model, as described by Hosmer, 137 Lemeshow, and Sturdivant. [24] Appraising to nonlinear relations found, we built a generalized 138 additive model (GAM), estimating linear and nonlinear effects. Instead of a single regression 139 coefficient, GAM estimates a k number of base functions, which in sum describes the functional 140 form of the relationship between dependent and independent variables.[25] We tested for 141 interaction effects using tensor products in the GAM model. Notably, the tensor smoothing 142 function (TI) calculates different k base functions for each variable included in the interaction 143 effect, and it is useful for variables with different scales. [24,25]

144

In a second approach, we used the classification and regression tree (CART) algorithm to find the most relevant variables associated with the clinical outcome.[26] We set the overall significance level at 5%. The sampling method was not probabilistic and consecutive. We defined the sample size by convenience. Thus, the analyses were exploratory. We used R version 4.0.2 software for statistical analyses.

150

151 **Results**

From March to July 2020, 1,000 patients were diagnosed with SARS-CoV-2 infection at HUM, and 650 met the inclusion criteria with in-hospital admittance and CBC measurement. We excluded seven patients because they met the exclusion criteria. Four of them had a history of anemia, two hematologic malignancies, and one permanent residency at low altitude (< 2,500 MASL), yielding 643 patients included in this study.

157

The median (interquartile range) age was 60 years old (46-73), and 52.56% of patients were male. The more frequent comorbidities were hypertension (35.76%), diabetes (18.04%), COPD (9.92%), and chronic kidney disease (CKD) (5.9%). The median MAP and SpO₂/FiO₂ were 92 mmHg (83.7-101.9) and 419 (359.5-438), respectively. Regarding the CBC on admission, the median white blood cell count (WBC) was 7.11 (5.29-9,71) x 10³ cells/µL, and the median concentration of Hb was 14.8 g/dL (13.5-15.9). Among the total sample, 123 patients (19.12%) died and 520 (80.87%) survived.

165

166 Table 1 shows the proportion of characteristics and median differences in vital signs and CBC by 167 discharge condition with an exploratory hypothesis test result. We found a statistically significant 168 difference in the proportion of males between survivors and nonsurvivors. Additionally, there was 169 statistically significant difference in age and the number of patients with a history of hypertension, 170 COPD, and CKD. Concerning vital signs, we found statistically significant differences in the 171 median respiratory rate, FiO₂, SpO₂, and SpO₂/FiO₂. Regarding CBC, there were differences between survivors and nonsurvivors patients in terms of median WBC, RBC count, absolute 172 173 lymphocyte count (ALC), absolute neutrophil count (ANC), Hb, NLR, and several percent white 174 blood cell relations.

175

Table 1 Demographic characteristics, comorbidity history, vital signs, and complete blood count
 by discharge condition in COVID-19 patients.

Variable	Alive n = 520(80.8%)	Dead n = 123(19.1%)	Total n (%) N = 643	P value*
Sex Female Male	260 (50%) 260 (50%)	45 (37%) 78 (63%)	305(47.4%) 338 (52.56%)	0.010
Age Median (IQR)	57 (42-69)	74 (62.5-82)	60 (46-73)	<0.001

C_{males} biotom $(n/2)$				I
Smoke history h (%) Current Former Never	12 (2%) 29 (6%) 472 (92%)	2 (1%) 11 (9%) 109 (90%)	13 (2.04%) 40 (6.29%) 582 (01-65%)	0.232
Comorbidities History n	(%)			
Hypertension	156 (30.0%)	74 (60.2%)	230 (35 76%)	<0.001
	130 (30.078)	74 (00.270)	230 (33.7078)	<0.001
Dyslipidemia	8 (1.5%)	6 (4.9%)	14 (2.17%)	0.053
Cardiovascular disease	25 (4.8%)	6 (4.9%)	31 (4.82%)	1.000
Heart failure	18 (3.5%)	7 (5.7%)	25 (3.88%)	0.373
Asthma	8 (1.5%)	1 (0.8%)	9 (1.39%)	0.850
COPD	31 (6.0%)	27 (22.0%)	58 (9.02%)	<0.001
Diabetes	86 (16.5%)	30 (24.4%)	117 (18.04%)	0.057
Cerebrovascular disease	9 (1.7%)	5 (4.1%)	14 (2.17%)	0.211
Atrial fibrillation	13 (2.5%)	6 (4.9%)	19 (2.95%)	0.269
Chronic kidney disease	21 (4.0%)	17 (13.8%)	38 (5.90%)	<0.001
Liver disease	4 (0.8%)	1(0.0%)	4 (0.62%)	0.735
Autoimmune disease	10 (1.9%)	5 (4.1%)	15 (2.33%)	0.279
Hypothyroidism	62 (11.9%)	22 (17.9%)	84 (13.06%)	0.106
HIV	7 (1.3%)	1 (0.8%)	8 (1.24%)	0.978
Psychiatric disease	10 (1.9%)	2 (1.6%)	12 (1.86%)	1.000
Vital Signs Median (IQR)			. ,	
Systolic blood pressure	127 (115-140)	131 (119-145)	128 (116-141)	0.073
Diastolic blood pressure	75 (66-84)	72 (63-82)	75 (66-83)	0.096
Mean blood pressure	92 (83.6-101.6)	92.1 (82.4- 102.6)	92 (83.7-101.9)	0.850
Heart rate	95 (82-106)	97 (80.5-109.5)	95 (82-106.5)	0.516
Respiratory rate	20 (18-20)	20 (18-22.5)	20 (18-20)	0.001
Temperature	36.5 (36.2-37.1)	36.5 (36.1- 37.05)	36.5 (36.2-37.1)	0.192
Fraction inspired O2 (FiO2)	21 (21-21)	21 (21-28)	21 (21-21)	<0.001
Peripheral O2 saturation (SpO2)	91 (87-94)	88 (78-91)	90 (86-93)	<0.001
SpO ₂ /FiO ₂	424 (386-443)	352 (286.5- 426.5)	419 (359.5-438)	<0.001
BMI	26.7 (24-30.1)	25.7 (23.1-29.3)	26.6 (23.6-30.1)	0.179
Complete Blood Count	Median (IQR)			
WBC	6.6 (5.23-8.97)	8.62(6.43.11.72)	7.11 (5.29-9.71)	<0.001
RBC count	5.06(4.69-5.48)	4.93(4.17-5.48)	5.04 (4.64-5.48)	0.019

Absolute lymphocyte count	1.23(0.9-1.62)	0.88(0.60-1.33)	1.18 (0.82-1.56)	<0.001
Absolute neutrophil count	4.56 (3.3-7)	6.82 (4.5-9.85)	4.96 (3.45-7.73)	<0.001
Hemoglobin	14.9 (13.7-15.9)	14.1 (12.5-15.8)	14.8 (13.5-15.9)	0.011
Hematocrit	44.5 (41.3-47.5)	43 (38.2-47.8)	44.4 (40.7-47.5)	0.052
Mean corpuscular volume	87.7 (84.9-90.9)	88 (85.2-91.6)	87.8 (85-91)	0.101
Platelets	223.5 (178-272)	209 (160.5- 277.5)	221 (177-273)	0.179
Neutrophil percentage	71.9 (60.6-81.3)	83.2 (75.1-88,3)	74.4 (62.4-83.2)	<0.001
Basophil percentage	0.2(0.1-0.4)	0.2(0.1-0.4)	0.2 (0.1-0.4)	0.597
Lymphocyte percentage	18.5 (11.5-27.8)	9.8 (6.85-16)	16.7 (10.2-26.35)	<0.001
Monocyte percentage	7.6 (5.1-10.3)	5.7 (4.05-8.4)	7.3 (4.8-10)	<0.001
Eosinophile percentage	0.1 (0-0.5)	0 (0-0.3)	0.1 (0-0.5)	0.002
Neutrophil to lymphocyte ratio	3.91(2.2-7.1)	8(4.6-12.9)	4.4(2.3-8.1)	<0.001

179 *Exploratory hypothesis testing for purposeful selection of covariates

IQR: Interquartile range, COPD: Chronic obstructive pulmonary disease, HIV: Human
 immunodeficiency virus infection, FiO2: Fraction inspired O2, SpO2: Peripheral O2 saturation,
 BMI: Body mass index, WBC: White blood cell count, RBC: Red blood cell.

183

184 We carried out a purposeful selection of covariates for modeling based on statistically significant 185 differences found.[24] We found that age, sex, history of hypertension, SpO2/FiO2, Hb, and NLR 186 were independently associated with in-hospital mortality. The relationship between age and mortality was linear. However, the association between SpO2/FiO2, Hb, and NLR and mortality 187 188 was nonlinear. Thus, as stated earlier, we performed a GAM that included linear and smoothened 189 terms. Moreover, we found a significant interaction term between SpO2/FiO2 and hemoglobin. 190 Table 2 shows the effects of the linear terms in the independent and interaction GAM. These 191 estimations were the same for both models. Table 3 shows the smoothed variables in both 192 models and the significance of its smoothed function.

193

195 Table 2 Linear terms of independent effects and interaction generalized additive model

Linear terms	Coefficient	P value	OR	CI 95%
Intercept	-2.661	<0.001		
Age	0.044	<0.001	1.05	1.03-1-06
Sex: Male	0.783	0.003	2.19	1.28–3.73
Hypertension: Yes	0.611	0.017	1.84	1.11–3.05

196 The estimated effects for linear terms, age, sex, and hypertension history were the same among

197 the independent effects model and interaction model.

198

199 Table 3 Smoothed terms of independent effects and interaction generalized additive model

Independent eff	fects model	Interaction model		
Smoothed terms	P Value ^a	Smoothed terms	P Value	
S ^b (Neutrophil-to-	<0.001	S(Neutrophil-to-	<0.001	
lymphocyte ratio)		lymphocyte ratio)		
S (SpO ₂ /FiO ₂)	<0.001	TI ^c (SpO2/FiO2, Hemoglobin)	0.011	
S (Hemoglobin)	<0.001			
R ² = 0.3. AIC = 470		R ² = 0.25	2, AIC= 495	

^aP value shown with smoothened and tensor terms tested the H_0 : f(x) = 0. ^bS(): Smoothed term;

201 °TI(): Tensor interaction term.

202

203 It is noteworthy that the model with the interaction term had a higher Akaike information criterion 204 (AIC) and a lower determination coefficient (R²) than the principal effects model, which came at 205 the cost of higher complexity. Smoothed variables and interaction effects from the GAM model 206 can be better understood visually. Figure 1 presents the functional form of the smoothened 207 variable's influence on mortality. Death probability had a positive correlation with NLR. Values of 208 SpO₂/FiO₂ present a sharp increase in the mortality risk under 350-320. Hemoglobin at admission 209 had a U-shaped correlation with mortality. Patients with low or high hemoglobin concentrations 210 were more prone to die during hospitalization. However, the significant interaction term showed 211 us that the Hb and SpO₂/FiO₂ effects on mortality were modified by each other.

212

213 Fig. 1. Partial effects of smoothed terms on mortality in GAM

Figure 1 shows the functional form of the partial effects on mortality of the smoothed terms in GAM. 1A) Positive correlation between NLR and mortality risk. 1B) Decreases in SpO₂/FiO₂ values lead to a sharp increase in death risk. 1C) U-shaped relationship between Hb concentration and mortality risk, patients with Hb either high or low values had an increased mortality risk. Inside parentheses are the smoothed term and its effective degrees of freedom (EDF), a summary statistic that reflects the degree of nonlinearity. NLR: Neutrophil to lymphocyte ratio, GAM: Generalized additive model.

221

222 The contour plot in Figure 2 shows how Hb modifies the SpO₂/FiO₂ effect on mortality. Notice how 223 patients with similar SpO₂/FiO₂ at admittance had a different likelihood of death according to their 224 Hb value at admission. For instance, death probability remained constant (10%) across all ranges 225 of SpO₂/FiO₂ values for patients with an Hb between 12-15 g/dL. The likelihood of death was also 226 10% for those with a high Hb but $SpO_2/FiO_2 > 400$. However, patients with $SpO_2/FiO_2 < 300$ and 227 Hb >15 g/dL had a 20% likelihood of death. This probability increased proportionally as the Hb 228 concentration rose. It increased to 80% of death likelihood for patients with SpO₂/FiO₂ of 300 and 229 Hb >20 g/dL and 90% for patients with $SpO_2/FiO_2 < 150$ and an Hb of approximately 18 g/dL. 230 Additionally, in patients with SpO₂/FiO₂ of 400 and Hb <10 g/dL, the death probability increased 231 proportionally as Hb decreased, increasing up to 70 to 90% for patients with an Hb of 232 approximately 5 g/dL. We further explored this interaction effect with a second approach, which is 233 explained below.

234

Fig. 2. Interaction effect between SpO₂/FiO₂ and Hb on mortality

Figure 2 shows a contour plot with estimated probabilities of death for given SpO2/FiO2 values at different hemoglobin concentrations. Curves show areas where the risk of death is similar. Higher likelihoods are shown in red, while green indicates lower likelihoods. Patients with similar SpO2/FiO2 values had different probabilities of death according to hemoglobin concentration. Notice how decreases in SpO2/FiO2 get worse as hemoglobin concentration rise. Blanks in the plot represent data that were not observed.

2	Λ	2
7	4	~

243 Figure 3 shows a CART model, a method that classifies patients according to their likelihood of 244 death using SpO₂/FiO₂, Hb, age, and NLR as independent variables. The patients with the 245 highest probability of death (90%) were those who had SpO₂/FiO₂ <324, were older than 62 246 years, and had an Hb >16 g/dL. Additionally, patients with an Hb <12 g/dl and NLR >4 had a 247 higher probability of death (57%). In comparison, patients with the lowest likelihood of death 248 (10%) were those who did have an SpO₂/FiO₂ >324 and an Hb >12 g/dL at admission. 249 Interestingly, the CART method also showed that the hemoglobin concentration at admittance 250 modified the SpO₂/FiO₂ effect on probability of death.

251

Fig. 3. Classification and regression tree of the mortality of COVID-19 patients.

Figure 3 Distribution of death and survival across COVID-19 patients. The CART showed seven differential clinical profiles using SpO_2/FiO_2 , age, Hb concentration, and NLR as predictor variables. Clinical profiles with a lower probability of death are shown in green, while red indicates the clinical profiles with a higher likelihood of death. Notice how hemoglobin concentrations both <12 g/dL and \geq 16 g/dL are features of the clinical profiles with higher mortality likelihood based upon SpO_2/FiO_2 admission value. Hb: Hemoglobin (g/dl), NLR: Neutrophil to lymphocyte ratio.

260 **Discussion**

This original research described the nonlinear relations and, to our knowledge, an unrecognized interaction effect between Spo₂/FiO₂ and Hb on the mortality of patients with SARS-CoV-2 acute respiratory infection. Using novel multivariate statistical methods to assess nonlinear relations, we found that Spo₂/FiO₂, Hb, NLR, age, history of hypertension, and male sex were independently associated with the probability of death. The Spo₂/FiO₂, Hb, and NLR values had a nonlinear relationship with the outcome in GAM. Interestingly, low or high Hb concentrations showed a sharp quadratic increase in the likelihood of death (Fig. 1). We found a significant interaction

between SpO₂/FiO₂ and Hb effects on mortality (Fig. 2). We explored this further using CART, which showed that older patients with a lower SpO₂/FiO₂ and a Hb \geq 16 g/dL had the highest probability of death (90%). Additionally, normoxic (SpO₂/FiO₂ >324) but anemic patients (<12 g/dl) with an NLR >4 had a higher probability of death (57%). Normoxic nonanemic patients (>12 g/dl) had, as expected, the lowest likelihood of death (10%).

273

274 The proportion of death among hospitalized patients was 19.12%, and the cumulative death 275 incidence between March and July was 95.6 per 500 patients admitted to HUM. The Centers for 276 Disease Control and Prevention (CDC) reported in-hospital mortality ranging from 8.6% to 23.4% 277 in approximately the same period. [27] Regarding the oxygenation index, we found a significant 278 difference in the median SpO₂/FiO₂ between survivors and nonsurvivors. Some authors have 279 proposed the SpO₂/FiO₂ ratio as a continuous noninvasive monitoring tool for assessing 280 oxygenation in acute respiratory failure, or its use as a surrogate for estimating PaO_2/FiO_2 in 281 sepsis.[28,29] The SpO₂/FiO₂ ratio showed good performance with an AUC =0.801 (95% CI 282 0.746–0.855) for early mechanical ventilation requirements in patients with COVID-19, even with 283 better performance than the ROX index. Its sequential assessment showed a sharp decline in 284 nonsurvivors compared to an increasing shift in survivors.[30] Catoire et al. described an 285 excellent performance AUC of 0.91 (95% CI 0.885–0.950) of SpO₂/FiO₂ to estimate PaO₂/FiO₂ 286 values in patients with COVID-19 patients.

287

We found a significant association between SpO₂/FiO₂ and mortality. The GAM showed a sharp increase in the probability of mortality as SpO₂/FiO₂ decreased (Fig. 1), with a slight decrease at values under 100. The CART model established a cut point of 324 to define higher-risk groups. Type I respiratory failure in acute respiratory distress syndrome (ARDS) is stratified by PaO₂/FiO₂ evaluation, although some authors have proposed a modified definition for scarce resource settings using SpO₂/FiO₂ assessment.[31] Berlin's definition has allowed stratifying patients based on oxygenation compromise. There is a correlation between disease severity measured by

PaO₂/FiO₂ and mortality risk. However, it has a limited prognostic performance with an AUC of
0.57 (95% CI 0.561-0.593).

297

For instance, patients with severe ARDS (PaO_2/FiO_2 values <100) have a differential prognosis according to distensibility and expiratory volume. Higher expiratory volume and lower distensibility distinguish a higher mortality risk group, even with similar PaO_2/FiO_2 . [32] Nevertheless, these measures require advanced monitoring, which is not frequently available in scarce resource settings. Numerous studies have explored other biomarkers to enhance prognostication in patients with ARDS.

304

Red bloodline characteristics have raised concern in the physiopathology of COVID-19 and ARDS. In our study, either high or low Hb values were associated with higher likelihood of death, giving a nonlinear, U-shaped correlation between hemoglobin concentration and probability of death in GAM (Fig. 1C). However, the oxygenation index measured by the SpO₂/FiO₂ ratio modified this effect. Patients with similar SpO₂/FiO₂ had different mortality probabilities according to Hb concentration (Fig. 2).

311

Taneri et al. conducted a meta-analysis including 139 observational studies. They reported a 312 313 weighted mean difference (WMD) of -4.08 g/L (CI -5.12; -305) between moderate and severe 314 cases in patients with COVID-19. However, among 27 studies, there were no significant 315 differences in the pooled mean Hb concentrations between survivors and nonsurvivors, with a 316 WMD of -0.26 g/L (95% CI -2.37; 1.85).[21] In an in silico analysis, Liu et al. proposed a direct 317 effect of SARS-CoV-2 proteins ORF1ab, ORF10, and ORF3a in the Hb beta chain competing 318 against iron. This leads to a functional loss of hemoglobin and hemolysis. However, given that 319 these hypotheses proposed a nondescribed protein-protein hemoglobin degradation pathway, 320 some authors criticized it for its flawed methods and unreliability.[33,34] In the same way, De 321 Martino et al. did not find differences in the hemoglobin dissociation curves or hemolytic

biomarkers between patients with COVID-19-related ARDS and patients with ARDS from other
 causes.[35]

324

325 Histopathological descriptions of the lung tissue of patients with ARDS describe the presence of 326 RBCs. However, they are considered a marker for the increased permeability of the endothelial-327 alveolar barrier. Nevertheless, recently, the role of RBCs and cell-free Hb has been discussed as 328 a central phenomenon in the progression of acute respiratory infection to sepsis, critical illness, 329 and ARDS pathogenesis. The proinflammatory state steers lipid peroxidation, pump damage, 330 changes in calcium influx, and 2,3-DPG concentrations. This leads to RBC membrane changes, 331 facilitating their aggregation, inducing thrombotic events, and hemolysis with cell-free hemoglobin and iron unstable (Fe 4+) group liberation. These perpetuate an injury cycle with nitric oxide 332 333 consumption, vasoconstriction, inflammation, and increased endothelial permeability.[36] 334 Oxidative and inflammatory damage, and thrombosis with cell aggregation in capillary beds, 335 might explain the harmful effect of polycythemia that we observed in our sample.

336

337 Furthermore, other RBC biomarkers are related to ARDS prognosis. Some authors have studied 338 red blood cell distribution width (RDW) and circulating nucleated red blood cells (NRBCs) as 339 prognostic markers. A RDW >14.5 was independently associated with mortality at 30 and 90 days 340 (OR 1.91, CI 95% 1.08–3.39 and 2.56, CI 95% 1.50–4.37, respectively).[37,38] The NRBCs are 341 biomarkers of increased erythropoietic activity. They are related to hypoxemia and inflammation. 342 A study reported a significant difference in the proportion of deaths (50.8% versus 27.3% [p 343 <0.001]) between patients with and without NRBCs. Additionally, patients with severe cases had 344 a higher number of NRBCs, and they were detectable for a longer time. Additionally, there was a 345 negative correlation between the NRBC absolute count and survival time.[39]

346

Otherwise, we found that a higher NLR was related to worse outcomes. Consistently, previous studies have proposed this relation as a biomarker of severe disease.[40,41] It is used in validated evaluation scales such as COVID-GRAM for predicting critical illness risk.[40] Kilercik et

al. evaluated the performance of CBC measures for predicting risk of COVID-19 severity and
mortality. They reported that an NLR >5.23 had a sensitivity and specificity for mortality of 85.6%
and 56.8%, respectively. Additionally, with a cutoff point of 4.4, NLR had a sensitivity of 78.5%
and specificity of 68.2% for predicting severe disease.[42]

354

355 A lower ALC is related to the risk of COVID-19 progression. The CALL score uses it as a variable 356 for predicting pneumonia progression.[43] Patients with COVID-19 who developed ARDS demonstrated sustained CD4+ and CD8+ lymphopenia compared to patients without COVID-19-357 358 related ARDS .[44] Additionally, the absolute counts of B, T, and natural killer (NK) cells were 359 found to be significantly lower in patients with severe COVID-19 cases than in patients with nonsevere COVID-19 cases.[8] Immune activation by long-term antigen exposure throughout life 360 361 is related to sterile and chronic low-grade inflammation associated with chronic diseases, 362 cardiovascular risk, obesity, and cancer.[45] This process leads to a senescent adaptive immune 363 system with a predominance of an innate response, which could generate an exaggerated inflammatory response leading to sepsis. The NLR could be a biomarker of this 364 365 predominance.[44,45]

366

367 We also found that male patients were more likely to die in the hospital than females. Analysis of 368 other coronaviruses, such as SARS and MERS, also showed an excess of mortality in male 369 patients. [46,47] Interestingly, the erythroid response to chronic high-altitude hypoxia might be 370 influenced by sex hormones. Chronic mountain sickness (CMS) is rare in Andean females of 371 reproductive age, but its incidence presents a sharp increase with menopause. Additionally, CMS 372 is more frequent in Andean male patients than in female patients. Estrogens might confer 373 protection against excessive erythrocytosis in CMS or Monge's disease. At physiologic 374 concentrations in vitro, estrogens were related to lower RBC counts than testosterone. Estrogens 375 regulate EPO, HIF1A, GATA1, VEGF, genes related to erythropoiesis and erythroid apoptosis 376 mechanisms.[48] These findings suggest that sex hormones moderate the erythropoietic

377 response of chronic exposure to hypoxia and may contribute to the mortality excess in male378 patients with COVID-19.

379

380 This study has some limitations. First, we only considered admission values as predictors of 381 mortality. Patients with COVID-19 might have different behaviors with several kinds of 382 intervention requirements that we did not observe, and which could modify the prognosis. 383 Additionally, we did not consider certain variables related to the Hb dissociation curve as PCO₂ or 384 acid-base status, which might be associated with residual confusion bias. Furthermore, we did 385 not consider the pharmacological history that could affect the baseline CBC. Lastly, given the 386 retrospective nature of our study, and since the data were gathered from clinical records, we could not guarantee a uniform measurement for each variable. It is necessary to note that no 387 388 effect can be associated with high-altitude exposure given the absence of a comparative group. 389 The variables studied might also be modified in chronic pulmonary disease or tobacco use. 390 However, including those variables in the purposeful selection of covariates for multivariate analysis showed us that they lacked significance. This study allowed us to hypothesize that the 391 392 adaptative mechanism for chronic hypoxia modifies the pathological process in respiratory 393 diseases. Further studies are required to understand this biological interaction.

394

395 **Conclusion**

396 This study explored the role of the oxygenation index and CBC biomarkers taken at admission as 397 predictors of in-hospital mortality. We found in GAM that SpO₂/FiO₂, Hb, and NLR were 398 independently associated with mortality following nonlinear trends. Both low and high Hb 399 concentrations showed a higher likelihood of death. Decreases in SpO₂/FiO₂ were associated 400 with a sharp increase in the likelihood of death. However, we found that the effects of Hb and 401 SpO₂/FiO₂ on mortality were modified by each other. For instance, patients with similar oxygen 402 index values had different death probabilities based on their Hb at admission. The likelihood of 403 death of patients with a low SpO₂/FiO₂ increased proportionally as Hb increased. The CART

model showed that patients with a SpO₂/FiO₂ >324 and an Hb >12 g/dl had the lowest mortality risk (10%). In contrast, normoxic but anemic patients with Hb <12 g/dl and NLR >4 had a higher probability of death (57%). Finally, patients whose SpO₂/FiO₂ was lower than 324, who were older than 62 years, and who had a Hb ≥16 g/dl had the highest mortality risk (90%).

408

409 Author contributions

- 410 AMPR and AMRS led and supervised the execution of the research. They contributed to
- 411 evidence interpretation, critical reviewing and commenting on the manuscript.
- 412 DRRL conceptualized the study, conducted the project, collected the data, interpreted the
- 413 evidence, and critically reviewed the manuscript.
- 414 NMG contributed to data curation, formal analysis, and visualization.
- 415 AFPA conceptualized the study, worked in data curation, formal analysis, visualization, evidence
- 416 interpretation, and manuscript drafting.
- 417 Acknowledgments
- 418 We thank Estefania Rodríguez Alvarino, Isabella Sanclemente Mariño, and Mateo Díaz Quiroz for
- 419 supporting the literature review, and Elizabeth Cruz Tapias for her work in image editing.

420 **Disclosure**

- 421 The authors report no conflicts of interest in this work.
- 422

423 **References**

- 424 1. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard
- 425 With Vaccination Data [Internet]. [cited 2021 Aug 22]. Available from:
- 426 https://covid19.who.int/
- 427 2. Colombia: WHO Coronavirus Disease (COVID-19) Dashboard With Vaccination Data |

428		WHO Coronavirus (COVID-19) Dashboard With Vaccination Data [Internet]. [cited 2021
429		Aug 22]. Available from: https://covid19.who.int/region/amro/country/co
430	3.	Instituto Nacional de Salud. Coronavirus Colombia [Internet]. 2020 [cited 2020 Sep 22].
431		Available from: https://www.ins.gov.co/Noticias/Paginas/Coronavirus.aspx
432	4.	Liu W, Tao ZW, Wang L, Yuan ML, Liu K, Zhou L, et al. Analysis of factors associated with
433		disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med
434		J (Engl) [Internet]. 2020 May 5 [cited 2021 Apr 13];133(9):1032–8. Available from:
435		/pmc/articles/PMC7147279/
436	5.	Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected
437		with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
438	6.	Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors
439		associated with hospital admission and critical illness among 5279 people with
440		coronavirus disease 2019 in New York City: Prospective cohort study. BMJ. 2020;369.
441	7.	Garibaldi BT, Fiksel J, Muschelli J, Robinson ML, Rouhizadeh M, Perin J, et al. Patient
442		Trajectories Among Persons Hospitalized for COVID-19: A Cohort Study. Ann Intern Med.
443		2021;174(1):33–41.
444	8.	Tian D-S, Qin C, Zhou L, Hu Z, Zhang S, Yang S, et al. Dysregulation of Immune
445		Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis
446		[Internet]. 2020 [cited 2021 Aug 25];71:762–8. Available from:
447		https://academic.oup.com/cid/article/71/15/762/5803306
448	9.	Yin Tan L, Vaani Komarasamy T, RMT Balasubramaniam V. Hyperinflammatory Immune
449		Response and COVID-19: A Double Edged Sword. [cited 2021 Nov 25]; Available from:
450		www.frontiersin.org
451	10.	Woolcott OO, Bergman RN. Mortality Attributed to COVID-19 in High-Altitude Populations.
452		High Alt Med Biol. 2020;21(4):409–16.
453	11.	Cano-Pérez E, Torres-Pacheco J, Fragozo-Ramos MC, García-Díaz G, Montalvo-Varela
454		E, Pozo-Palacios JC. Negative Correlation between Altitude and COVID-19 Pandemic in
455		Colombia: A Preliminary Report. Am J Trop Med Hyg [Internet]. 2020 Oct 26 [cited 2021

456	Aug 22];103(6):2347–9. Available fro	m:

- 457 https://www.ajtmh.org/view/journals/tpmd/103/6/article-p2347.xml
- 458 12. Intimayta-Escalante C, Rojas-Bolivar D, Hancco I. Letter to the Editor: Influence of Altitude
- 459 on the Prevalence and Case Fatality Rate of COVID-19 in Peru. High Alt Med Biol.
- 460 2020;21(4):426–7.
- 461 13. Ortiz-Prado E, Patricio Fernandez Naranjo R, Vasconez E, Simbañ a-Rivera K, Correa-
- 462 Sancho T, Alex Lister ii, et al. Analysis of Excess Mortality Data at Different Altitudes
- 463 During the COVID-19 Outbreak in Ecuador. https://home.liebertpub.com/ham [Internet].
- 464 2021 Dec 13 [cited 2021 Dec 28];22(4):406–16. Available from:

465 https://www.liebertpub.com/doi/abs/10.1089/ham.2021.0070

466 14. Trompetero González AC, Mejía EC, Benavides Pinzón WF, Serrato M, Landinéz MP,

467 Rojas J. Comportamiento de la concentración de hemoglobina, el hematocrito y la

468 saturación de oxígeno en una población universitaria en Colombia a diferentes Alturas.

469 Nutr Hosp. 2015;32(5):2309–18.

- 470 15. Julian CG. High Altitude During Pregnancy. Clin Chest Med [Internet]. 2011;32(1):21–31.
 471 Available from: http://dx.doi.org/10.1016/j.ccm.2010.10.008
- 472 16. Pun M, Guadagni V, Bettauer KM, Drogos LL, Aitken J, Hartmann SE, et al. Effects on
 473 cognitive functioning of acute, subacute and repeated exposures to high altitude. Front
 474 Physiol. 2018;9(AUG):1–15.
- 475 17. Windsor JS. Heights and haematology: the story of haemoglobin at altitude. Postgr Med J
 476 [Internet]. 2007 [cited 2021 Feb 26];83:148–51. Available from: www.postgradmedj.com
- 47718.West JB. Are Permanent Residents of High Altitude Fully Adapted to Their Hypoxic
- 478 Environment? High Alt Med Biol. 2017;18(2):135–9.
- 479 19. Acevedo LE, Solarte I. Gasimetria arterial en adultos jóvenes a nivel de Bogotá. Acta
 480 Médica Colomb. 1984 Jan;9(1).
- 481 20. Johanna TR, Hurtado C, Salazar T, De La Peña M. Valores Normales de Gases Arteriales
 482 en Bogotá. Umbral Científico [Internet]. 2007 [cited 2021 Dec 21];(10):94–102. Available
 483 from: https://www.redalyc.org/articulo.oa?id=30401008

404 ZI. TAIICH FE. GUIICZ-OCHUA SA. LIAHAI E. NAYUHUHI FF. NUAS LZ. NUA-DIAZ Z

- 485 Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis. Eur J
- 486 Epidemiol [Internet]. 2020;35(8):763–73. Available from: https://doi.org/10.1007/s10654487 020-00678-5
- 488 22. Hayden SJ, Albert TJ, Watkins TR, Swenson ER. Anemia in Critical Illness: Insights into
- 489 Etiology, Consequences, and Management. Am J Respir Crit Care Med [Internet]. 2012
- 490 May 15 [cited 2021 Dec 28];185(10):1049. Available from: /pmc/articles/PMC5448578/
- 491 23. Fuentes S, Chowdhury YS. Fraction of Inspired Oxygen. StatPearls [Internet]. 2021 Jan
- 492 17 [cited 2021 Aug 24]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK560867/
- 493 24. Hosmer DW, Lemeshow S, Sturdivant RX. Applied Logistic Regression. Vol. 47,
- 494 Biometrics. 1991. 1632 p.
- 495 25. Wood SN. Generalized additive models. 2° Ed. Blitzstein JK, Faraway JJ, Tanner M, Zidek
 496 J. editors. Vol. 1, Statistical Science. CRC Press; 1986. 297–310 p.
- 497 26. Leo B, Jerome F, Richard A O, Charles J S. Classification and Regressión Trees. Vol. 1.
 498 Florida: Chapman & Hall; 1984. 1–384 p.
- 499 27. COVID-19 Hospital Data In-hospital mortality among confirmed COVID-19 encounters by
 500 week [Internet]. [cited 2021 Aug 24]. Available from:
- 501 https://www.cdc.gov/nchs/covid19/nhcs/hospital-mortality-by-week.htm
- 50228.Rice TW, Wheeler AP, Bernard GR, Hayden DL, Schoenfeld DA, Ware LB. Comparison of503the SpO2/FIO2 ratio and the PaO 2/FIO2 ratio in patients with acute lung injury or ARDS.
- 504 Chest. 2007;132(2):410–7.
- 505 29. Pratik P. Pandharipande, Shintani AK, Hagerman HE, Jacques PJS, Rice TW, Sanders
- 506 NW, et al. Derivation and validation of SpO2 /FiO2 ratio to impute for PaO2 / FiO2 ratio in
- 507 the respiratory component of the Sequential Organ Failure Assessment (SOFA) Score.
- 508 Crit Care Med [Internet]. 2009;23(1):1–7. Available from:
- 509 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624763/pdf/nihms412728.pdf
- 510 30. Lu X, Jiang L, Chen T, Wang Y, Zhang B, Hong Y, et al. Continuously available ratio of
- 511 SpO2/FiO2serves as a noninvasive prognostic marker for intensive care patients with

512 COVID-19. Respir Res. 2020;21(1):1–4.

- 513 31. Riviello ED, Kiviri W, Twagirumugabe T, Mueller A, Banner-Goodspeed VM, Officer L, et
- al. Hospital incidence and outcomes of the acute respiratory distress syndrome using the
- 515 Kigali modification of the Berlin definition. Am J Respir Crit Care Med. 2016;193(1):52–9.
- 516 32. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute
- 517 respiratory distress syndrome: The Berlin definition. JAMA J Am Med Assoc.
- 518 2012;307(23):2526–33.
- 33. Wenzhong L, Hualan L. COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures
 the Porphyrin to Inhibit Human Heme Metabolism. ChemRxiv. 2020;105.
- 521 34. R R. Flawed methods in "COVID-19: Attacks the 1-Beta Chain of Hemoglobin and
- 522 Captures the Porphyrin to Inhibit Human Heme Metabolism." 2020 Apr 14 [cited 2021 Jun
- 523 19]; Available from: https://europepmc.org/article/PPR/PPR151013
- 524 35. DeMartino AW, Rose JJ, Amdahl MB, Dent MR, Shah FA, Bain W, et al. No evidence of 525 hemoglobin damage by SARS-CoV-2 infection. Haematologica. 2020;105(12):2769–73.
- 526 36. Janz DR, Ware LB. The role of red blood cells and cell-free hemoglobin in the
- 527 pathogenesis of ARDS [Internet]. Vol. 3, Journal of Intensive Care. BioMed Central Ltd.;
- 528 2015 [cited 2021 Feb 26]. p. 20. Available from:
- 529 http://www.jintensivecare.com/content/3/1/20
- 530 37. Yu XS, Chen ZQ, Hu YF, Chen JX, Xu WW, Shu J, et al. Red blood cell distribution width
- is associated with mortality risk in patients with acute respiratory distress syndrome based
- 532 on the Berlin definition: A propensity score matched cohort study. Hear Lung [Internet].
- 533 2020 Sep 1 [cited 2021 Mar 19];49(5):641–5. Available from:
- 534 https://pubmed.ncbi.nlm.nih.gov/32434701/
- 535 38. Wang B, Gong Y, Ying B, Cheng B. Relation between Red Cell Distribution Width and
- 536 Mortality in Critically III Patients with Acute Respiratory Distress Syndrome. Biomed Res
- 537 Int [Internet]. 2019 [cited 2021 Mar 19];2019. Available from:
- 538 https://pubmed.ncbi.nlm.nih.gov/31016186/
- 539 39. Menk M, Giebelhäuser L, Vorderwülbecke G, Gassner M, Graw JA, Weiss B, et al.

540		Nucleated red blood cells as predictors of mortality in patients with acute respiratory
541		distress syndrome (ARDS): an observational study. Ann Intensive Care [Internet]. 2018
542		Dec 1 [cited 2021 Mar 19];8(1):42. Available from: /pmc/articles/PMC5869325/
543	40.	Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and validation of a
544		clinical risk score to predict the occurrence of critical illness in hospitalized patients with
545		COVID-19. JAMA Intern Med. 2020;180(8):1081–9.
546	41.	Kuri-Cervantes L, Betina Pampena M, Meng W, Rosenfeld AM, G Ittner CA, Weisman AR,
547		et al. Comprehensive mapping of immune perturbations associated with severe COVID-
548		19. Sci Immunol [Internet]. 2020 [cited 2021 Aug 25];5. Available from:
549		http://immunology.sciencemag.org/
550	42.	Kilercik M, Demirelce Ö, Serdar MA, Mikailova P, Serteser M. A new haematocytometric
551		index: Predicting severity and mortality risk value in COVID-19 patients. PLoS One.
552		2021;16(8 August):1–19.
553	43.	Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P, et al. Prediction for Progression Risk in
554		Patients With COVID-19 Pneumonia: The CALL Score. Clin Infect Dis [Internet]. 2020 Sep
555		12 [cited 2021 Apr 13];71(6):1393–9. Available from:
556		https://academic.oup.com/cid/article/71/6/1393/5818317
557	44.	Hue S, Beldi-Ferchiou A, In' I, Bendib I, Surenaud M, Fourati S, et al. Uncontrolled Innate
558		and Impaired Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory
559		Distress Syndrome. Am J Respir Crit Care Med [Internet]. 2017 [cited 2021 Aug
560		25];202:1509–19. Available from: www.atsjournals.org.
561	45.	Fulop T, Larbi A, Dupuis G, Page A Le, Frost EH, Cohen AA, et al. Immunosenescence
562		and inflamm-aging as two sides of the same coin: Friends or Foes? [Internet]. Vol. 8,
563		Frontiers in Immunology. Frontiers Media S.A.; 2018 [cited 2021 Jun 15]. Available from:
564		https://pubmed.ncbi.nlm.nih.gov/29375577/
565	46.	Karlberg J, Chong DSY, Lai WYY. Do Men Have a Higher Case Fatality Rate of Severe
566		Acute Respiratory Syndrome than Women Do? Am J Epidemiol [Internet]. 2004 Feb 1
567		[cited 2021 Jun 15];159(3):229–31. Available from:

568 https://pubmed.ncbi.nlm.nih.gov/14742282/

- Alghamdi IG, Hussain II, Almalki SS, Alghamdi MS, Alghamdi MM, El-Sheemy MA. The
 pattern of Middle east respiratory syndrome coronavirus in Saudi Arabia: A descriptive
 epidemiological analysis of data from the Saudi Ministry of Health. Int J Gen Med
 [Internet]. 2014 Aug 20 [cited 2021 Jun 15];7:417–23. Available from:
 https://pubmed.ncbi.nlm.nih.gov/25187734/
 Azad P, Villafuerte FC, Bermudez D, Patel G, Haddad GG. Protective role of estrogen
- against excessive erythrocytosis in Monge's disease. Exp Mol Med [Internet]. 2021 [cited
- 576 2021 Nov 24];53:125–35. Available from: https://doi.org/10.1038/s12276-020-00550-2
- 577

578 **Notes:**

579 Abbreviations: AIC: Akaike information criteria; ALC: Absolute lymphocyte count; ANC: Absolute 580 neutrophil count; ARDS: Acute respiratory distress syndrome; BMI: Body mass index; CART: 581 Classification and regression tree; CBC: Complete blood count; CKD: Chronic kidney disease; CMS: Chronic mountain sickness; COPD: Chronic obstructive pulmonary disease; EPO: 582 583 Erythropoietin; FiO2: Fraction inspired O2; GAM: Generalized additive model; Hb: Hemoglobin 584 concentration (g/dL); HIF-1a: Hypoxia-inducible factor $1-\alpha$; HIV: Human immunodeficiency virus; 585 HUM: Hospital Universitario Mayor; MAP: Mean arterial pressure; MASL: Meters above sea level; 586 NK: Natural killer cells; NLR: Neutrophil to lymphocyte ratio; NRBCs: Nucleated red blood cells 587 circulating; PCO2: Partial CO2 pressure; RBC: Red blood cells count; RDW: Red blood cell 588 distribution width; SpO2: Peripheral O2 saturation; VEGF: Vascular-endothelial growth factor; 589 WBC: White blood cell count; WMD: Weighted mean difference.

- 590
- 591
- 592 593
- 594
- 595



Figure 1

Death probability



Figure 2



Figure 3